Found 486 results in Expert Content

Summary: Phase-appropriate CMC-related activities can facilitate the transition from early development through commercialization.

Summary: Experts introduce Catalent’s new OptiDose™ Design Solution, an integrated dose form design strategy based on an analyzation of your molecule, patient, and market.

Summary: Drug development requires integrating multi-disciplinary business, regulatory and scientific activities. To successfully support a client’s program, it is imperative to provide advice and services that support all three in the context of a program’s goal. In this exclusive webinar presented by Jim Spavins...

Summary: Catalent expands its inhalation platform through the acquisition of a Boston-area facility, providing spray drying, powder encapsulation and blister packaging for Dry Powder Inhaler (DPI) capsules.

Summary: Integrated approach from development to clinical and benefits of working with a single integrated provider.

Summary: The transition from early phase to late phase of a small molecule program plays a pivotal role in determining a program’s ultimate success. Early planning strategies can help minimize the burdens often faced in that transition. The implementation of modeling tools...

This article discusses how quality by design (QbD) can be built into inhalation product development to ensure a drug and device are safe and effective.

Catalent CEO John Chiminski to talks about the year ahead, offering projections for what 2021 holds in store for the biopharma industry.

The development of orally administered small molecules is more challenging as an many have poor aqueous solubility and bioavailability.

This article discusses why roller compaction is a robust option when developing a tablet or capsule formulation.